<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481257</url>
  </required_header>
  <id_info>
    <org_study_id>06-2017-086</org_study_id>
    <nct_id>NCT03481257</nct_id>
  </id_info>
  <brief_title>Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel</brief_title>
  <official_title>Comparison of Shear Stress-induced Thrombotic and Thrombolytic Effect d Thrombolytic Effect Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B
      (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with
      study drugs on top of aspirin (100mg/d) for 1 month. VerifyNowÂ® and Global thrombosis test
      were performed at day 2 and 1 month after administration of study drugs. The investigators
      compared aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU), occlusion time (OT) which
      reflects shear stress-induced thrombotic activity, and lysis time (LT) which showed
      endogenous lytic activity between the two strategies at both time points.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Actual">February 4, 2018</completion_date>
  <primary_completion_date type="Actual">January 4, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occlusion time</measure>
    <time_frame>1 month</time_frame>
    <description>Global thrombosis test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lysis time</measure>
    <time_frame>1 month</time_frame>
    <description>Global thrombosis test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusion time</measure>
    <time_frame>Day 2</time_frame>
    <description>Global thrombosis test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lysis time</measure>
    <time_frame>Day 2</time_frame>
    <description>Global thrombosis test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P2Y12 reaction unit</measure>
    <time_frame>Day 2 and 1 month</time_frame>
    <description>VerifyNow test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspirin reaction unit</measure>
    <time_frame>Day 2 and 1 month</time_frame>
    <description>VerifyNow test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>major adverse cardiovascular outcome</measure>
    <time_frame>1 month</time_frame>
    <description>composites of cardiac death, myocardial infarction and target lesion revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>BARC bleeding</measure>
    <time_frame>1 month</time_frame>
    <description>ARC definition</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <description>ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + very low dose rivaroxaban</arm_group_label>
    <description>ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Fifty-six patients from 452 patients who underwent percutaneous coronary intervention (PCI)
        due to ACS in Seoul National University Bundang Hospital. ( April 2017~ January 2018)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were diagnosed with acute coronary syndrome and underwent percutaneous
             coronary intervention

        Exclusion Criteria:

          -  Patients administered with glycoprotein IIb/IIIa inhibitiors

          -  Patients with atrial fibrillation

          -  Patients with high risk of bleeding at the physician's discretion

          -  Patients with renal impairment (estimated GFR &lt;30ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Won Suh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Won Suh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

